Tuesday, August 6, 2013

Deep Research Report: Antibody Target, Technology & Pipeline Database Market Share 1-Year Subscription

Description

Subscription to La Merie Publishing’s proprietary Antibody Database provides online access to information about more than 2,400 project entries for therapeutic antibodies on the market and in research & development. Pre-established and free search functions allow to identify antibodies according to their

  • Technology (e.g. antibody-drug conjugate, bispecific, isotype, phage display)
  • Target (e.g. Her2, CD20, TNF, PD-1/PD-L1)
  • Pipelines (selected by target, therapeutic area, company, technology)
  • Sales (for marketed antibodies)
  • R&D Phase (clinical phases, market, preclinical)
  • Territory (countrywise)
  • Therapeutic Area (e.g. infectious, oncology, gastrointestinal)
  • Drug Code/Name (for individual molecules)




Project listing in a tabular format:

  • Drug Codes
  • Target
  • Class of Compound
  • Company
  • Territory
  • Therapeutic Area
  • Indication
  • R&D Phase

Therapeutic Areas:

  • Cardiovascular & blood
  • Dermatology
  • Gastrointestinal
  • Genitourinary, renal & gynecology
  • Infectious & toxicology
  • Metabolism & endocrine
  • Neurology & psychiatry
  • Oncology
  • Ophthalmology & otorhinolaryngology
  • Orthopedics, dental, anesthesia & surgery
  • Pulmonary & respiratory
  • Rheumatoid & autoimmune

Predefined Technologies of the Scroll-Down Menu - examples:

  • Antibody-Drug Conjugates per Payload (e.g. Auristatin, PBD)
  • Bispecific Antibodies
  • Oligo- and Polyclonal Antibodies
  • In vitro generated Antibodies (phage display)
  • Fab Antibodies
  • Fc-Fusion Proteins
  • Agonist Antibodies
  • Transgenic Mouse Antibodies (e.g. XenoMouse, VelocImmune Mouse, KM Mouse)
  • Human Cell-Derived Antibodies



To Buy The Copy of This Report Visit : http://www.marketresearchreports.biz/analysis/172485        


Contact

M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-997-4948

No comments:

Post a Comment